Amphastar P (AMPH)vsNovartis AG ADR (NVS)
AMPH
Amphastar P
$26.68
-2.59%
HEALTHCARE · Cap: $1.03B
NVS
Novartis AG ADR
$146.88
-0.80%
HEALTHCARE · Cap: $271.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7666% more annual revenue ($56.69B vs $730.02M). NVS leads profitability with a 22.5% profit margin vs 10.8%. AMPH appears more attractively valued with a PEG of 2.77. AMPH earns a higher WallStSmart Score of 59/100 (C).
AMPH
Buy59
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.6%
Fair Value
$39.51
Current Price
$26.68
$12.83 discount
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$146.88
$53.48 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 21.6%
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
4.7% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AMPH
The strongest argument for AMPH centers on Price/Book, P/E Ratio, Operating Margin.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : AMPH
The primary concerns for AMPH are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
AMPH carries more volatility with a beta of 0.92 — expect wider price swings.
AMPH is growing revenue faster at 5.4% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AMPH scores higher overall (59/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amphastar P
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?